Novartis Pumps $15M Into Israeli Stem Cell Research Firm
The Swiss drug maker Novartis will invest an extra $15 million in Gamida Cell, an Israeli developer of stem cell therapies, Gamida said.
Novartis last year invested $35 million in the company for a 15 percent stake, the Tachles Jewish weekly of Switzerland reported this week. The deal could reach $600 million if Novartis exercises a buyout option that expires in 2016.
The $15 million investment will be used to advance Gamida Cell’s clinical programs, including the development of an experimental treatment for patients with high risk hematological malignancies, or blood cancers such as leukemia and lymphoma and sickle cell disease.
Gamida plans to initiate a Phase III clinical trial with NiCord in mid-2016, according to Reuters.
Novartis will not have rights or options to Gamida Cell products or technology under the terms of the agreement.
Other Gamida shareholders include Israeli firms that have been the subjects of politically motivated divestment by European business, including Elbit Imaging and Teva Pharmaceutical Industries.
The Forward is free to read, but it isn’t free to produce
I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward.
Now more than ever, American Jews need independent news they can trust, with reporting driven by truth, not ideology. We serve you, not any ideological agenda.
At a time when other newsrooms are closing or cutting back, the Forward has removed its paywall and invested additional resources to report on the ground from Israel and around the U.S. on the impact of the war, rising antisemitism and polarized discourse.
This is a great time to support independent Jewish journalism you rely on. Make a Passover gift today!
— Rachel Fishman Feddersen, Publisher and CEO
Make a Passover Gift Today!
Dive In
-
Fast Forward FSU shooting suspect used neo-Nazi imagery on social media, ADL finds
-
Fast Forward Pope Francis’ final speech called for ceasefire and hostage release in Gaza war
-
Fast Forward Israeli army fires deputy commander after finding ‘operational errors’ in killing of 15 Gazans
-
Fast Forward ‘F–k Israel’ message displayed at Coachella music festival and streamed to millions
Most Popular
- 1
News Student protesters being deported are not ‘martyrs and heroes,’ says former antisemitism envoy
- 2
News Who is Alan Garber, the Jewish Harvard president who stood up to Trump over antisemitism?
- 3
Fast Forward Suspected arsonist intended to beat Gov. Josh Shapiro with a sledgehammer, investigators say
- 4
Opinion What Jewish university presidents say: Trump is exploiting campus antisemitism, not fighting it
In Case You Missed It
-
Fast Forward FSU shooting suspect used neo-Nazi imagery on social media, ADL finds
-
Fast Forward Pope Francis’ final speech called for ceasefire and hostage release in Gaza war
-
Opinion Shackled, imprisoned and subjected to false accusations, Kilmar Abrego Garcia recalls the fate of Captain Alfred Dreyfus
-
Opinion The dangerous Nazi legend behind Trump’s ruthless grab for power
-
Shop the Forward Store
100% of profits support our journalism
Republish This Story
Please read before republishing
We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines.
You must comply with the following:
- Credit the Forward
- Retain our pixel
- Preserve our canonical link in Google search
- Add a noindex tag in Google search
See our full guidelines for more information, and this guide for detail about canonical URLs.
To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at [email protected], subject line “republish,” with any questions or to let us know what stories you’re picking up.